Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG

NCT06107374 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Non Small Cell Lung Cancer

Interventions

DRUG: [18F]F-AraG

Sponsor

CellSight Technologies, Inc.